Ozempic (Semaglutide): What It Is, Trial History and Regulatory Status

Evidence tier: Established (FDA-approved; multiple randomized controlled trials).

Ozempic is the brand name Novo Nordisk uses for its once-weekly subcutaneous formulation of the active ingredient semaglutide. It belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class of prescription medicines used in type 2 diabetes. This page summarises what the published literature and product labelling describe about semaglutide — what it is, how the pivotal trials were designed and what they reported, what adverse events appeared in those trials, and how the approved products that share the same active ingredient differ from one another. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

What Ozempic Is and How It Works

Semaglutide is a modified analogue of human GLP-1, a gut-derived incretin hormone released after eating. A 2019 review of the discovery and development programme described how researchers modified the native GLP-1 sequence with amino acid substitutions and a fatty-acid side chain so the molecule resisted enzymatic degradation and bound reversibly to albumin, producing a much longer duration of action than the natural hormone (PMID 31031702). That same review traced the lineage from liraglutide, an earlier once-daily analogue, to semaglutide, which was engineered for once-weekly administration (PMID 31031702).

A 2024 systematic review of the clinical pharmacokinetics of semaglutide reported an elimination half-life of approximately one week, which is the property that underpins once-weekly subcutaneous dosing, and it also summarised the pharmacokinetics of the oral tablet formulation, which relies on an absorption enhancer to permit gastrointestinal uptake (PMID 38952487).

Mechanistically, GLP-1 receptor agonists are described as increasing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying and acting on central appetite circuits. A 2020 rodent study reported that semaglutide lowered body weight in rodents through distributed neural pathways rather than a single hypothalamic site, with the researchers mapping brain regions engaged by the drug (PMID 32213703). A 2023 review of semaglutide for obesity described reduced appetite and energy intake as the principal drivers of the weight changes observed in clinical studies (PMID 34942372).

Approved indications and dates

A 2018 drug profile documenting semaglutide's first global approval reported that once-weekly subcutaneous semaglutide was approved in the United States in December 2017 for glycaemic control in adults with type 2 diabetes, alongside diet and exercise (PMID 29363040). The US prescribing information for Ozempic also carries an indication to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Ozempic itself is not the product approved for weight management; a separate higher-dose presentation of the same active ingredient carries that indication, as described below.

Trial History as Published

The SUSTAIN programme in type 2 diabetes

The phase 3 development programme for injectable semaglutide in type 2 diabetes was conducted under the SUSTAIN name. The 2018 approval profile reported that once-weekly subcutaneous semaglutide 0.5 mg and 1 mg improved glycaemic control and reduced body weight in adults with type 2 diabetes across that programme, and that these trials supported the first regulatory approvals (PMID 29363040). The profile also noted that an oral formulation of semaglutide was under development at the time of writing (PMID 29363040).

Obesity trials at higher weekly doses

Trials of semaglutide 2.4 mg once weekly in adults with overweight or obesity were run under the STEP programme and supported a separate brand for chronic weight management. A 2022 review of that product reported that semaglutide 2.4 mg once weekly produced clinically meaningful reductions in body weight compared with placebo when combined with lifestyle intervention, and described the 2021 US approval of that higher-dose presentation for chronic weight management in adults meeting body-mass-index criteria (PMID 34706925). A 2023 review in cardiovascular medicine summarised the same body of evidence and reported that semaglutide produced greater weight reduction than earlier GLP-1 receptor agonists studied for obesity (PMID 34942372).

Meta-analysis in obesity without diabetes

A 2022 systematic review and meta-analysis pooled randomised trials of semaglutide for weight loss in people with obesity but without diabetes, and the researchers reported significantly greater reductions in body weight with semaglutide than with placebo, with gastrointestinal events the most frequently reported adverse events across the included studies (PMID 36578889). The authors of that analysis noted that the evidence base at the time was drawn from trials of limited duration relative to the chronic nature of obesity (PMID 36578889).

SELECT: long-term weight change

The SELECT trial studied semaglutide 2.4 mg once weekly in adults with overweight or obesity and established cardiovascular disease but without diabetes. A 2024 analysis of the trial's weight outcomes reported that weight loss with semaglutide continued for roughly the first year, plateaued, and was then sustained over approximately four years of follow-up, with reductions in waist circumference reported alongside the weight changes (PMID 38740993). The study was notable because it provided far longer randomised follow-up than the earlier obesity trials (PMID 38740993).

Coverage of off-label use

A 2023 JAMA medical news article described the rapid rise in public attention to semaglutide and discussed the distinction between the diabetes indication and weight-loss use, including off-label prescribing and questions clinicians were fielding about weight regain after discontinuation (PMID 37099334).

Adverse Events in Trials and on the Label: What Studies Report

Across the published programme, gastrointestinal effects dominate the adverse-event tables. The 2022 meta-analysis in obesity without diabetes reported nausea, vomiting, diarrhoea and constipation as the most common adverse events with semaglutide relative to placebo (PMID 36578889). The 2023 obesity review similarly reported that gastrointestinal symptoms were the leading reason participants discontinued treatment in weight-management trials (PMID 34942372).

A 2021 review dedicated to the safety of semaglutide examined the signals raised across the development programme, and the researchers discussed gastrointestinal tolerability, gallbladder-related events, pancreatitis, diabetic retinopathy complications observed in the cardiovascular outcomes setting, and the thyroid C-cell tumour findings seen in rodent studies of GLP-1 receptor agonists (PMID 34305810). That review concluded that the overall safety profile reported in trials was broadly consistent with the GLP-1 receptor agonist class (PMID 34305810).

Post-approval case reports add individual observations that trials were not powered to detect. A 2025 case report described semaglutide-associated liver injury in a single patient, with the authors reporting the clinical course and the diagnostic reasoning used to attribute the injury to the drug (PMID 40761336). A 2024 case report described hyperemesis gravidarum in a pregnancy occurring during semaglutide exposure, and the authors reported severe vomiting requiring management (PMID 38249445). Single case reports describe what happened to one person and cannot establish how often an event occurs.

On the product labelling, semaglutide carries a boxed warning concerning thyroid C-cell tumours observed in rodents, with contraindications in people who have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; the underlying rodent C-cell findings behind that warning were among the safety issues discussed in the 2021 safety review (PMID 34305810). Whether any individual's history makes a GLP-1 receptor agonist appropriate is a question for a licensed prescriber, not for a summary page.

Regulatory Status

Semaglutide's first global approval was granted in the United States in December 2017 for type 2 diabetes, as documented in the 2018 approval profile (PMID 29363040). Approvals in other jurisdictions followed, and a higher-dose weekly presentation for chronic weight management was approved in the United States in 2021 under a separate brand name, as described in the 2022 product review (PMID 34706925). An oral tablet formulation of the same active ingredient is also marketed for type 2 diabetes, and its pharmacokinetics were reviewed alongside the injectable form in 2024 (PMID 38952487).

Semaglutide is a prescription-only medicine in the United States, the European Union and other major markets. Supply of GLP-1 receptor agonists has at times been constrained by demand; the 2023 JAMA news article described the surge in public interest in semaglutide for weight loss and the pressures that accompanied it (PMID 37099334). As a general regulatory matter, compounded preparations are not FDA-approved products: they have not been reviewed by the agency for safety, effectiveness or manufacturing quality, and they are not the same thing as an approved branded product even when a compounder describes the active ingredient by the same name. Nothing here is legal advice; questions about the legality or appropriateness of any specific product belong with a licensed professional.

How Ozempic Differs from Sibling Products with the Same Active Ingredient

Several distinct approved products contain semaglutide. They differ in route, strength, indication and brand name, which is why they are not interchangeable and why prescribing decisions rest with a clinician.

The clinical trial evidence also differs by product. The diabetes indication rests on the SUSTAIN programme reported in the approval profile (PMID 29363040), while the weight-management indication rests on the higher-dose trials summarised in obesity reviews and meta-analyses (PMID 34942372, PMID 36578889).

What the Published Evidence Does Not Settle

Several questions remain open in the literature. Durability beyond the trial windows is one: the 2024 SELECT weight analysis reported sustained weight loss over roughly four years in a cardiovascular-risk population, which is longer than most obesity trials but still finite (PMID 38740993). Weight trajectory after stopping treatment was raised as an open clinical question in the 2023 JAMA news coverage (PMID 37099334). Rare adverse outcomes such as the drug-induced liver injury described in a 2025 case report cannot have their frequency estimated from single cases (PMID 40761336), and exposure during pregnancy remains poorly characterised, with case-level reporting such as the 2024 hyperemesis gravidarum report standing in for systematic data (PMID 38249445). Mechanistic work in animals, including the 2020 rodent mapping study of distributed neural pathways, describes biology rather than clinical outcomes (PMID 32213703).

Consulting a Prescriber

Everything above describes published trial findings, review articles and product labelling. It does not describe what any particular person should do. Whether a GLP-1 receptor agonist is appropriate, which product and strength a label supports, how an individual's medical history intersects with contraindications and warnings, and how any treatment should be monitored are clinical decisions that belong to a reader and their prescriber. Adverse events, including those reported in the safety literature summarised here, are matters to raise with a licensed clinician rather than to self-assess (PMID 34305810).

PeptideU is not affiliated with or endorsed by Novo Nordisk. Ozempic is a trademark of its owner. This page is for educational purposes only and is not medical advice; consult a licensed physician or your prescriber about any medication.

References

• Semaglutide: First Global Approval (Drugs, 2018)
• The Discovery and Development of Liraglutide and Semaglutide (Frontiers in Endocrinology, 2019)
• Semaglutide lowers body weight in rodents via distributed neural pathways (JCI Insight, 2020)
• Safety of Semaglutide (Frontiers in Endocrinology, 2021)
• Wegovy (semaglutide): a new weight loss drug for chronic weight management (Journal of Investigative Medicine, 2022)
• Semaglutide for the treatment of obesity (Trends in Cardiovascular Medicine, 2023)
• Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis (Journal of the ASEAN Federation of Endocrine Societies, 2022)
• As Ozempic's Popularity Soars, Here's What to Know About Semaglutide and Weight Loss (JAMA, 2023)
• Semaglutide-induced Hyperemesis Gravidarum (JCEM Case Reports, 2024)
• Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial (Nature Medicine, 2024)
• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Semaglutide-Induced Liver Injury (ACG Case Reports Journal, 2025)